Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs

The following video is brought to you courtesy of the Bloomberg TV Markets and Finance YouTube Channel. Click the video below to watch it now.

Apr.16 — Merck & Co. is cementing its lead in lung cancer therapy, fending off rival Bristol-Myers Squibb Co. after new data is released that could reshape treatment of the deadly disease. Bloomberg’s Taylor Riggs reports on “Bloomberg Markets: Balance of Power.”

Comments are closed.